MX368167B - Moduladores de receptores de glucocorticoides de azadecalina octahidro fusionada. - Google Patents

Moduladores de receptores de glucocorticoides de azadecalina octahidro fusionada.

Info

Publication number
MX368167B
MX368167B MX2016006725A MX2016006725A MX368167B MX 368167 B MX368167 B MX 368167B MX 2016006725 A MX2016006725 A MX 2016006725A MX 2016006725 A MX2016006725 A MX 2016006725A MX 368167 B MX368167 B MX 368167B
Authority
MX
Mexico
Prior art keywords
azadecaline
octahydro
fused
receptor modulators
glucocorticoid receptor
Prior art date
Application number
MX2016006725A
Other languages
English (en)
Other versions
MX2016006725A (es
Inventor
Hunt Hazel
Walters Iain
Gourdet Benoit
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of MX2016006725A publication Critical patent/MX2016006725A/es
Publication of MX368167B publication Critical patent/MX368167B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención provee compuestos de azadecalina octahidrofusionada y métodos para usar los compuestos como moduladores de receptores de glucocorticoides.
MX2016006725A 2013-11-25 2014-11-21 Moduladores de receptores de glucocorticoides de azadecalina octahidro fusionada. MX368167B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361908333P 2013-11-25 2013-11-25
US201461985035P 2014-04-28 2014-04-28
PCT/US2014/066759 WO2015077530A1 (en) 2013-11-25 2014-11-21 Octahydro fused azadecalin glucocorticoid receptor modulators

Publications (2)

Publication Number Publication Date
MX2016006725A MX2016006725A (es) 2016-09-09
MX368167B true MX368167B (es) 2019-09-23

Family

ID=53180165

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016006725A MX368167B (es) 2013-11-25 2014-11-21 Moduladores de receptores de glucocorticoides de azadecalina octahidro fusionada.

Country Status (20)

Country Link
US (8) US10047082B2 (es)
EP (4) EP4219494B1 (es)
JP (6) JP6516743B2 (es)
KR (1) KR102352737B1 (es)
CN (2) CN106029066B (es)
AU (1) AU2014352915B2 (es)
BR (1) BR112016011826B1 (es)
CA (1) CA2931302C (es)
DK (2) DK3848027T3 (es)
ES (3) ES2943542T3 (es)
FI (1) FI3848027T3 (es)
IL (1) IL245848B (es)
MX (1) MX368167B (es)
MY (1) MY180141A (es)
PH (1) PH12016500968B1 (es)
PL (3) PL3074011T3 (es)
PT (2) PT3848027T (es)
RU (1) RU2674983C1 (es)
WO (1) WO2015077530A1 (es)
ZA (1) ZA201604026B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12514849B2 (en) 2018-12-19 2026-01-06 Corcept Therapeutics Incorporated Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US12226412B2 (en) 2012-05-25 2025-02-18 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
MX368167B (es) 2013-11-25 2019-09-23 Corcept Therapeutics Inc Moduladores de receptores de glucocorticoides de azadecalina octahidro fusionada.
CN107530339B (zh) 2015-03-30 2021-03-16 科赛普特治疗学股份有限公司 糖皮质激素受体拮抗剂联合糖皮质激素用于治疗肾上腺功能不全
JP6847120B2 (ja) * 2016-03-01 2021-03-24 コーセプト セラピューティクス， インコーポレイテッド チェックポイントインヒビターを強化するためのグルココルチコイドレセプターモジュレーターの使用
CN106478464B (zh) * 2016-08-30 2018-06-05 黄河三角洲京博化工研究院有限公司 一种2-氟-6-三氟甲基苯磺酰氯的制备方法
US9943505B2 (en) 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer
MX2019010732A (es) 2017-03-09 2019-11-01 Corcept Therapeutics Inc Uso de moduladores de receptor de glucocorticoide en el tratamiento de tumores secretores de catecolamina.
US10413540B2 (en) 2017-03-31 2019-09-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat cervical cancer
US20180325891A1 (en) * 2017-05-10 2018-11-15 Corcept Therapeutics, Inc. Octahydro azadecalin formulations
MX393313B (es) 2017-06-20 2025-03-24 Corcept Therapeutics Inc Metodos de tratamiento de tumores neuroepiteliales usando moduladores selectivos del receptor de glucocorticoide.
WO2019199891A1 (en) * 2018-04-10 2019-10-17 Duke University Lasofoxifene treatment of breast cancer
ES3038908T3 (en) * 2018-04-23 2025-10-15 Corcept Therapeutics Inc Methods of preparing regioselective n-alkyl triazoles
US10981918B2 (en) * 2018-07-20 2021-04-20 Grünenthal GmbH Further substituted triazolo quinoxaline derivatives
IL263184A (en) 2018-11-21 2020-05-31 Yarden Yosef Method of treating cancer and compositions for same
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
WO2020132046A1 (en) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
EP3927345A4 (en) 2019-02-22 2022-12-21 Corcept Therapeutics Incorporated Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
US12440487B2 (en) 2019-10-16 2025-10-14 Corcept Therapeutics Incorporated Method of normalizing the neutrophil to lymphocyte ratio in cancer patients with a selective glucocorticoid receptor antagonist
WO2021119432A1 (en) 2019-12-11 2021-06-17 Corcept Therapeutics Incorporated Methods of treating antipsychotic-induced weight gain with miricorilant
CA3162636A1 (en) 2019-12-21 2021-06-24 Andreas G. MORAITIS Treatment of, and differential diagnosis between, acth-dependent cushing's syndrome and acth-independent cushing's syndrome
KR20220133275A (ko) 2020-01-29 2022-10-04 코어셉트 쎄라퓨틱스 인코포레이티드 선택적 글루코코르티코이드 수용체 조절제 (sgrm) 및 항체 체크포인트 억제제를 사용한 부신피질 암종의 치료
MX2022009781A (es) * 2020-02-10 2022-09-09 Corcept Therapeutics Inc Metodos para estimular una respuesta antitumoral utilizando un modulador selectivo del receptor de glucocorticoides.
US11787780B2 (en) 2020-06-22 2023-10-17 Corcept Therapeutics Incorporated Quaternary indazole glucocorticoid receptor antagonists
WO2022134033A1 (en) 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
CN116829556A (zh) * 2021-02-03 2023-09-29 江苏恒瑞医药股份有限公司 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用
IL313667A (en) 2021-12-21 2024-08-01 Corcept Therapeutics Inc Glucocorticoid receptor antagonists INDAZOL CYCLES
US12098144B2 (en) 2021-12-21 2024-09-24 Corcept Therapeutics Incorporated Piperazine indazole glucocorticoid receptor antagonists
KR20250073629A (ko) 2022-10-06 2025-05-27 코어셉트 쎄라퓨틱스 인코포레이티드 글루코코르티코이드 수용체 조절제의 제형
EP4608402A1 (en) 2022-10-28 2025-09-03 Corcept Therapeutics Incorporated Treatments for amyotrophic lateral sclerosis using dazucorilant
KR20250144469A (ko) * 2023-02-17 2025-10-10 코어셉트 쎄라퓨틱스 인코포레이티드 헌팅턴병 및 이의 증상을 치료하기 위한 방법 및 조성물
US20240390341A1 (en) * 2023-05-22 2024-11-28 Corcept Therapeutics Incorporated Methods for treating adrenal gland tumors
WO2025152964A1 (en) * 2024-01-15 2025-07-24 Insilico Medicine Ip Limited Novel compounds as glucocorticoid receptor modulators and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS322220B1 (es) 1954-11-30 1957-04-11
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
IL72729A (en) 1983-09-26 1988-02-29 Lilly Co Eli Trans(+_)octahydropyrazole-ring alkylated pyrazoloquinolines,their preparation and pharmaceutical compositions containing them
GB8828669D0 (en) * 1988-12-08 1989-01-11 Lilly Industries Ltd Organic compounds
JP3160941B2 (ja) 1991-06-17 2001-04-25 東レ株式会社 カルバゾール誘導体および免疫抑制剤
FR2697252B1 (fr) 1992-10-28 1994-12-09 Fournier Ind & Sante Dérivés de 1,2,3,5,6,7,8,8a-octahydro-5,5,8a-triméthyl-(8abeta)-6-isoquinolineamine, leur procédé de préparation et leur utilisation en thérapeutique.
EP0712402B1 (en) 1993-08-06 2002-04-10 Smithkline Beecham S.p.A. Hydroisoquinoline derivatives
EP1512683B1 (en) 1998-03-10 2011-08-31 Research Triangle Institute Novel opiate compounds, methods of making and methods of use
GB9911053D0 (en) 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
US20040048830A1 (en) * 2000-11-02 2004-03-11 Mingqiang Zhang Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders
WO2003015692A2 (en) 2001-07-17 2003-02-27 Smithkline Beecham Corporation Crystallized glucocorticoid receptor ligand binding domain polypeptide and screening methods employing same
DK1408981T3 (da) * 2001-07-23 2009-01-12 Corcept Therapeutics Inc Fremgangsmåder til forebyggelse af vægtforögelse som fölge af antipsykotiske midler
US6679935B2 (en) * 2001-08-14 2004-01-20 Apex Advanced Technologies, Llc Lubricant system for use in powdered metals
AU2003214879B2 (en) 2002-01-22 2008-02-07 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
WO2005023254A1 (en) 2003-09-03 2005-03-17 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same
CA2552419C (en) 2004-01-09 2013-04-23 Corcept Therapeutics, Inc. Azadecalin glucocorticoid receptor modulators
ES2313317T3 (es) 2004-03-09 2009-03-01 Corcept Therapeutics, Inc. Moduladores del receptor de glucocorticoides de azadecalina de anillo condensado.
ATE519744T1 (de) * 2005-04-05 2011-08-15 Hoffmann La Roche 1h-pyrazol-4-carbonsäure-amide, deren herstellung und verwendung als 11-beta-hydroxysteroid- dehydrogenase-hemmer
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
EP2209780B1 (en) * 2007-11-01 2014-01-01 Bristol-Myers Squibb Company Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and/or nf- kappa b activity and use thereof
CN101990541A (zh) * 2008-02-07 2011-03-23 百时美施贵宝公司 糖皮质激素受体、AP-1和/或NF-κB活性的稠合杂芳基调节剂及其用途
US8461172B2 (en) 2009-05-12 2013-06-11 Corcept Therapeutics, Inc. Solid forms and process for preparing
US8710035B2 (en) * 2010-03-24 2014-04-29 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
WO2012027702A1 (en) 2010-08-27 2012-03-01 Corcept Therapeutics, Inc. Pyridyl-amine fused azadecalin modulators
CA2821524A1 (en) 2011-01-07 2012-07-12 Corcept Therapeutics, Inc. Combination steroid and glucocorticoid receptor antagonist therapy
WO2013130420A1 (en) 2012-02-27 2013-09-06 Corcept Therapeutics, Inc. Phenyl heterocycloalkyl glucocorticoid receptor modulators
RU2639867C2 (ru) 2012-05-25 2017-12-25 Корсепт Терапьютикс, Инк. Конденсированные с гетероарилкетонами азадекалины - модуляторы глюкокортикоидных рецепторов
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
MX368167B (es) 2013-11-25 2019-09-23 Corcept Therapeutics Inc Moduladores de receptores de glucocorticoides de azadecalina octahidro fusionada.
US9943505B2 (en) * 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12514849B2 (en) 2018-12-19 2026-01-06 Corcept Therapeutics Incorporated Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound

Also Published As

Publication number Publication date
US11370789B2 (en) 2022-06-28
IL245848B (en) 2020-08-31
US20190048004A1 (en) 2019-02-14
EP3074011B1 (en) 2019-07-24
US10787449B2 (en) 2020-09-29
AU2014352915B2 (en) 2018-03-15
US10047082B2 (en) 2018-08-14
EP3074011A1 (en) 2016-10-05
IL245848A0 (en) 2016-07-31
JP2023011052A (ja) 2023-01-20
PL3560493T3 (pl) 2021-10-04
KR20160089506A (ko) 2016-07-27
JP6516743B2 (ja) 2019-05-22
AU2014352915A1 (en) 2016-06-30
US20190135805A1 (en) 2019-05-09
CA2931302A1 (en) 2015-05-28
US20210139478A1 (en) 2021-05-13
US20150148341A1 (en) 2015-05-28
BR112016011826B1 (pt) 2022-09-27
EP3074011A4 (en) 2017-05-31
PT3074011T (pt) 2019-09-17
DK3848027T3 (da) 2023-05-01
EP4219494B1 (en) 2026-03-25
US11560379B2 (en) 2023-01-24
EP3560493B1 (en) 2021-03-31
PL3074011T3 (pl) 2020-01-31
PL3848027T3 (pl) 2023-07-24
US12139486B2 (en) 2024-11-12
JP2024170470A (ja) 2024-12-10
PT3848027T (pt) 2023-05-11
US20200361935A1 (en) 2020-11-19
EP3848027A1 (en) 2021-07-14
US20230167111A1 (en) 2023-06-01
RU2674983C1 (ru) 2018-12-14
ES2743620T3 (es) 2020-02-20
CN106029066B (zh) 2019-03-15
RU2016123449A (ru) 2017-12-28
ES2869172T3 (es) 2021-10-25
KR102352737B1 (ko) 2022-01-17
CN109761976B (zh) 2021-11-23
US10323034B2 (en) 2019-06-18
CN109761976A (zh) 2019-05-17
US20250034140A1 (en) 2025-01-30
MY180141A (en) 2020-11-23
EP3560493A1 (en) 2019-10-30
FI3848027T3 (fi) 2023-05-04
BR112016011826A2 (es) 2017-08-08
JP2019094355A (ja) 2019-06-20
PH12016500968B1 (en) 2019-11-08
NZ720969A (en) 2021-05-28
JP2018012734A (ja) 2018-01-25
CA2931302C (en) 2021-12-07
ZA201604026B (en) 2019-03-27
JP2016537394A (ja) 2016-12-01
ES2943542T3 (es) 2023-06-14
JP2021073315A (ja) 2021-05-13
CN106029066A (zh) 2016-10-12
EP4219494A1 (en) 2023-08-02
US20190241563A1 (en) 2019-08-08
MX2016006725A (es) 2016-09-09
EP3848027B1 (en) 2023-04-05
WO2015077530A1 (en) 2015-05-28
DK3074011T3 (da) 2019-09-30
PH12016500968A1 (en) 2016-07-18

Similar Documents

Publication Publication Date Title
MX368167B (es) Moduladores de receptores de glucocorticoides de azadecalina octahidro fusionada.
CL2018000595A1 (es) Anticuerpos anti-pd1 y métodos de uso
ES2930298T3 (es) Moduladores del receptor de glucocorticoides de azadecalina condensada con heteroaril-cetona
CL2017001118A1 (es) Receptores quimericos de antígeno anti–cldn y métodos de uso
IL250754B (en) Solid forms of a toll-like receptor modulator
CR20140479A (es) Moduladores del receptor del estrogeno y sus usos
PT3539961T (pt) Derivados de amida policíclica como inibidores de cdk9
DK3533792T3 (da) Krystallinske former af en androgenreceptormodulator
UA109931C2 (xx) Піримідинциклогексильні модулятори глюкокортикоїдних рецепторів
EP3442971C0 (en) ESTROGEN RECEPTOR MODULATORS
CL2015002125A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
CL2018001481A1 (es) Nuevos anticuerpos anti-claudina y sus métodos de uso
HUE042443T2 (hu) GPR6 tetrahidropiridopirazin-modulátorai
UY33957A (es) Moduladores de los receptores de hormonas nucleares
UY34625A (es) Dispositivo con nucleo y recubrimiento para la liberacion de farmacos
DK2964229T3 (da) Benzoimidazol-2-yl-pyrimidinmodulatorer af histamin-h4 receptoren
HRP20181596T1 (hr) Tiazolopirimidinoni kao modulatori aktivnosti nmda receptora
HRP20190147T1 (hr) Benzoksazinon amidi kao modulatori mineralokortikodnih receptora
GT201400067A (es) Moduladores selectivos del receptor androgeno
CR20150008A (es) Indolecarbonitrilos como moduladores selectivos recptores de androgeno
UY34646A (es) Compuestos de espirohidantoína y su uso como moduladores selectivos del receptor de andrógenos
CO7190237A2 (es) Moduladores del receptor de glucocorticoides de azadecalina fusionada de heteroaril-cetona
TH1601004335B (th) อุปกรณ์จ่ายน้ำมันเชื้อเพลิงยานพาหนะ
ITMI20120786A1 (it) Modulatori del recettore gpr17

Legal Events

Date Code Title Description
FG Grant or registration